JAK2 Inhibition in the Treatment of Myelofibrosis

The mechanism of action of CYT387, a novel JAK1 and JAK2 inhibitor, in the treatment of myeloproliferative neoplasms. Janus kinases frequently mediate signaling in several diseases. Animation done for Toronto biotechnology company, YM Biosciences.